RAPPRapport Therapeutics, Inc.
$30.68+16% 1Y
$30.68
$24.3752 weeks$52.44
RAPP in its own filings
Nothing in RAPP's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
45
Events found in the filings · across 231 filings · the record starts in 2024
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Apr 24, 2024
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- SEC comment-letter activity12 occurrences
- 2025-07-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update.Earnings release · press release
- May 7, 2026Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update.Earnings release · press release
- Apr 21, 2026On April 21, 2026, the Company announced results from the 8-week follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures (“FOS”)Regulation FD disclosure · Form 8-K
- Mar 10, 2026Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Jan 7, 2026On January 7, 2026, Rapport Therapeutics, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s effective shelf registration statement on Form S-3 (File No. 333-288444) (the “Registration Statement”)Other event · Form 8-K
- Jan 7, 2026On January 7, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the “Investors” page of the Company’s website at www.rapportrx.com.Regulation FD disclosure · Form 8-K
- Nov 6, 2025Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update.Earnings release · press release
- Sep 10, 2025On September 9, 2025, Rapport Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated (collectively, the “Underwriters”), related to an underwritten public …Material agreement entered · Form 8-K
- Sep 8, 2025Effective September 8, 2025, the Company terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333-288444) (the “Registration Statement”) and related to the shares of the Company’s common stock, par value $0.001 per share (“Common …Other event · Form 8-K
- Sep 8, 2025On September 8, 2025, the Company announced topline data from its Phase 2a clinical trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry